Universal Biosensors, Inc. ARBN 121 559 993

1 Corporate Avenue Rowville Victoria 3178 Australia

Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com Universal Biosensors

ASX Announcement 30 September 2016

ASX: UBI

RELEASE OF RESTRICTED SHARES AND EXPIRY OF UNLISTED OPTIONS

The Company wishes to advise of the following changes in its securities:

- Release of 2,040 restricted shares of common stock
- Lapsing of the following options without exercise:
 - o 115,992 Options (US\$0.26, 18 September 2016)
 - o 12,000 Options (A\$0.70, 19 August 2018)
 - o 5,000 Options (A\$0.94, 28 June 2019)
 - o 5,000 Options (A\$1.72, 9 November 2019)
 - o 20,000 Options (A\$1.37, 9 March 2018)
 - o 12,000 Options (A\$0.73, 13 September 2019)
 - o 4,000 Options (A\$0.17, 13 August 2021)
 - o 6,666 Options (A\$0.23, 29 January 2022)

The capital structure of the Company following the release of the restricted shares and expiry of the unquoted securities is as follows:

Quoted Securities

175,699,104 shares of common stock traded in the form of CDIs

Unquoted Securities

| Number | Instrument | Exercise Price | Expiry Date |
|-----------|-------------------|----------------|--------------------|
| 505,980 | Restricted Shares | N/A | N/A |
| 529,000 | Employee Options | \$1.18 | 22-Mar-17 |
| 525,000 | Employee Options | \$1.20 | 18-Sep-17 |
| 645,000 | Employee Options | \$0.89 | 16-Mar-18 |
| 102,000 | Employee Options | \$0.70 | 19-Aug-18 |
| 8,000 | Employee Options | \$0.50 | 16-Feb-19 |
| 50,001 | Employee Options | \$0.00 | 14-May-19 |
| 388,334 | Employee Options | \$0.00 | 28-Jun-19 |
| 698,667 | Employee Options | \$0.94 | 28-Jun-19 |
| 1,095,000 | Employee Options | \$1.72 | 9-Nov-19 |
| 50,000 | Employee Options | \$1.60 | 10-Feb-17 |
| 216,000 | Employee Options | \$1.58 | 10-Nov-17 |
| 91,667 | Employee Options | \$0.00 | 10-Nov-17 |
| 213,000 | Employee Options | \$1.37 | 9-Mar-18 |
| 66,000 | Employee Options | \$1.00 | 21-Sep-18 |
| 222,500 | Employee Options | \$0.89 | 17-Nov-18 |
| 100,000 | Employee Options | \$0.00 | 17-Nov-18 |



| 50,000 | Employee Options | \$0.75 | 12-Mar-19 |
|-----------|------------------|--------|-----------|
| 74,000 | Employee Options | \$0.73 | 13-Sep-19 |
| 270,000 | Employee Options | \$1.09 | 12-Nov-19 |
| 100,000 | Employee Options | \$0.00 | 12-Nov-19 |
| 24,000 | Employee Options | \$0.79 | 11-Mar-20 |
| 30,000 | Employee Options | \$0.71 | 12-Nov-19 |
| 290,000 | Employee Options | \$0.49 | 11-Dec-20 |
| 160,000 | Employee Options | \$0.00 | 11-Dec-20 |
| 80,000 | Employee Options | \$0.17 | 13-Aug-21 |
| 352,500 | Employee Options | \$0.23 | 29-Jan-22 |
| 160,000 | Employee Options | \$0.00 | 29-Jan-22 |
| 382,500 | Employee Options | \$0.45 | 13-Dec-22 |
| 9,035,000 | Employee Options | \$0.50 | 20-Apr-23 |
| 4,500,000 | Warrants | \$1.00 | 19-Dec-20 |

-Ends-

Enquiries:

Mr Salesh Balak: 03 9213 9000

About Universal Biosensors

For additional information regarding Universal Biosensors, refer to: http://www.universalbiosensors.com/. Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.